Sugen低氧诱导肺动脉高压小鼠模型中免疫细胞亚群的动态变化

doi:10.3969/j.issn.1006-5725.2026.08.014

Abstract

Abstract:

Objective To investigate the dynamic changes of immune cell subsets in a mouse model of pulmonary hypertension （PH） induced by Sugen-hypoxia （SuHx）. Methods A SuHx-PH mouse model was established through intraperitoneal injection of Sugen 5416， followed by exposure to hypoxia. Mouse lung tissues were collected prior to modeling and at 1 week （h1w）， 2 weeks （h2w）， 3 weeks （h3w）， and 4 weeks （h4w） post-modeling. Flow cytometry was employed to detect the proportional alterations of immune cell subsets （including T cells， B cells， macrophages， eosinophils （EOS）， neutrophils （Neu）， natural killer （NK） cells， and innate lymphoid cells （ILCs） within CD45⁺ immune cells. Results Compared with the control group， the immune cell subsets in SuHx model mice demonstrated significant temporal changes. Among these， the total CD11c⁺F4/80⁺ macrophages and interstitial macrophages （IM， SIGLECF^-） showed a significant decreasing tendency as the modeling time progressed； the cell levels of alveolar macrophages （AM， SIGLECF⁺） continuously increased （P < 0.05）； EOS， ILCs， Neu， and CD4⁺T cells displayed a significant fluctuating pattern， with significant differences between groups （P < 0.05）. Conclusions The proportions of immune cell subsets in the lung tissues of SuHx-PH mice exhibit significant temporal changes， indicating that different immune cells may play stage-specific roles in the progression of PH. This study offers a foundation for a more in-depth understanding of the immunoinflammatory mechanism of PH and the identification of potential immune intervention targets.

Key words: Sugen-hypoxia model, pulmonary hypertension, immune cells, flow cytometry

CLC Number:

R543.2

Jie LIU,Xin XUE,Yu GUO,Zhenqiang GAO,Hanxiao ZHANG,Muzhi ZHANG,Huanyu LONG,Jialu LÜ,Mengyu XU,Yufeng JIA,Ye CUI,Wei WANG,Ying SUN,Lei WANG. Dynamic changes of immune cell subsets in a mouse model of Sugen-hypoxia-induced pulmonary hypertension[J]. The Journal of Practical Medicine, 2026, 42(8): 1407-1414.

Figures/Tables 8

Fig.1

Tab.1

Tab.2

Fig.2

Tab.3

Fig.3

Tab.4

Fig.4

References 25

[1]	TUDER R M. Pulmonary vascular remodeling in pulmonary hypertension［J］. Cell Tissue Res， 2017， 367（3）： 643-649. doi：10.1007/s00441-016-2539-y . doi: 10.1007/s00441-016-2539-y
[2]	罗志梅，刘虹延，孙得胜. 一种肺血管基因敲减动物模型的构建及在肺动脉高压中的运用［J］. 实用医学杂志， 2023， 39（4）： 404-409. doi：10.3969/j.issn.1006-5725.2023.04.003 . doi: 10.3969/j.issn.1006-5725.2023.04.003
[3]	张嘉莹，樊勇，张卓莉. 肺动脉高压发病机制中的肺血管重塑［J］. 中华临床免疫和变态反应杂志， 2023， 17（1）： 50-55. doi：10.3969/j.issn.1673-8705.2023.01.010 . doi: 10.3969/j.issn.1673-8705.2023.01.010
[4]	徐明艳，韩校鹏，刘英丽，等. 慢性阻塞性肺疾病急性加重期并发肺动脉高压的危险因素［J］. 实用医学杂志， 2022， 38（19）： 2467-2471.doi：10.3969/j.issn.1006-5725.2022.19.017 . doi: 10.3969/j.issn.1006-5725.2022.19.017
[5]	ZAWIA A， ARNOLD N D， WEST L， et al. Altered macrophage polarization induces experimental pulmonary hypertension and is observed in patients with pulmonary arterial hypertension［J］. Arterioscler Thromb Vasc Biol， 2021， 41（1）： 430-445. doi：10.1161/ATVBAHA.120.314639 . doi: 10.1161/ATVBAHA.120.314639
[6]	LI C， LIU P， SONG R， et al. Immune cells and autoantibodies in pulmonary arterial hypertension［J］. Acta Biochim Biophys Sin， 2017， 49（12）： 1047-1057. doi：10.1093/abbs/gmx095 . doi: 10.1093/abbs/gmx095
[7]	TARASEVICIENE-STEWART L， KASAHARA Y， ALGER L， et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension［J］. FASEB J， 2001， 15（2）： 427-438. doi：10.1096/fj.00-0343com . doi: 10.1096/fj.00-0343com
[8]	陈子宜，孙红燕，康品方，等.肺动脉高压动物实验模型的研究进展［J/OL］.实验动物与比较医学，1-18［2026-03-02］..
[9]	COSSARIZZA A， CHANG H D， RADBRUCH A， et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies （second edition）［J］. Eur J Immunol， 2019， 49（10）： 1457-1973. doi：10.1002/eji.201970107 . doi: 10.1002/eji.201970107
[10]	SORKHDINI P， KLUBOCK-SHUKLA K， SHETH S， et al. Type 2 innate immunity promotes the development of pulmonary fibrosis in Hermansky-Pudlak syndrome［J］. JCI Insight， 2024， 9（22）： e178381. doi：10.1172/jci.insight.178381 . doi: 10.1172/jci.insight.178381
[11]	IKUTANI M， SHIMIZU S， OKADA K， et al. Characterization of long-term interleukin-33 administration as an animal model of pulmonary arterial hypertension［J］. Biochem Biophys Res Commun， 2024， 734： 150750. doi：10.1016/j.bbrc.2024.150750 . doi: 10.1016/j.bbrc.2024.150750
[12]	LI N， LI Q， BAI J， et al. The multiple organs insult and compensation mechanism in mice exposed to hypobaric hypoxia［J］. Cell Stress Chaperones， 2020， 25（5）： 779-791. doi：10.1007/s12192-020-01117-w . doi: 10.1007/s12192-020-01117-w
[13]	SERHAN C N， BRAIN S D， BUCKLEY C D， et al. Resolution of inflammation： State of the art， definitions and terms［J］. FASEB J， 2007， 21（2）： 325-332. doi：10.1096/fj.06-7227rev . doi: 10.1096/fj.06-7227rev
[14]	KUANG M， CHEN Y， XING Y， et al. Echocardiographic evaluation of right heart failure which might be associated with DNA damage response in SU5416-hypoxia induced pulmonary hypertension rat model［J］. Respir Res， 2023， 24（1）： 202. doi：10.1186/s12931-023-02501-7 . doi: 10.1186/s12931-023-02501-7
[15]	秦崇，潘磊，李佳，等. 低压低氧肺动脉高压形成中CD4⁺T细胞亚群的变化［J］. 标记免疫分析与临床， 2024， 31（9）： 1580-1588. doi：10.11748/bjmy.issn.1006-1703.2024.09.003 . doi: 10.11748/bjmy.issn.1006-1703.2024.09.003
[16]	AYASS M A， TRIPATHI T， ZHU K， et al. T helper （Th） cell profiles and cytokines/chemokines in characterization， treatment， and monitoring of autoimmune diseases［J］. Methods， 2023， 220： 115-125. doi：10.1016/j.ymeth.2023.11.003 . doi: 10.1016/j.ymeth.2023.11.003
[17]	TAMOSIUNIENE R， MANOUVAKHOVA O， MESANGE P， et al. Dominant role for regulatory T cells in protecting females against pulmonary hypertension［J］. Circ Res， 2018， 122（12）： 1689-1702. doi：10.1161/CIRCRESAHA.117.312058 . doi: 10.1161/CIRCRESAHA.117.312058
[18]	SHU T， ZHANG J， ZHOU Y， et al. Eosinophils protect against pulmonary hypertension through 14-HDHA and 17-HDHA［J］. Eur Respir J， 2023， 61（3）： 2200582. doi：10.1183/13993003.00582-2022 . doi: 10.1183/13993003.00582-2022
[19]	陈睿迪，王炜，张若旸. 巨噬细胞在间质性肺疾病相关肺动脉高压中的作用［J］. 微生物学免疫学进展， 2025， 53（4）： 87-93. doi：10.13309/j.cnki.pmi.2025.04.014 . doi: 10.13309/j.cnki.pmi.2025.04.014
[20]	SHAPOURI-MOGHADDAM A， MOHAMMADIAN S， VAZINI H， et al. Macrophage plasticity， polarization， and function in health and disease［J］. J Cell Physiol， 2018， 233（9）： 6425-6440. doi：10.1002/jcp.26429 . doi: 10.1002/jcp.26429
[21]	ZHANG M Q， WANG C C， PANG X B， et al. Role of macrophages in pulmonary arterial hypertension［J］. Front Immunol， 2023， 14： 1152881. doi：10.3389/fimmu.2023.1152881 . doi: 10.3389/fimmu.2023.1152881
[22]	FLORENTIN J， COPPIN E， VASAMSETTI S B， et al. Inflammatory macrophage expansion in pulmonary hypertension depends upon mobilization of blood-borne monocytes［J］. J Immunol， 2018， 200（10）： 3612-3625. doi：10.4049/jimmunol.1701287 . doi: 10.4049/jimmunol.1701287
[23]	AL-QAZAZI R， LIMA P D A， PRISCO S Z， et al. Macrophage-NLRP3 activation promotes right ventricle failure in pulmonary arterial hypertension［J］. Am J Respir Crit Care Med， 2022， 206（5）： 608-624. doi：10.1164/rccm.202110-2274OC . doi: 10.1164/rccm.202110-2274OC
[24]	DANG B， GAO Q， ZHANG L， et al. The glycolysis/HIF-1α axis defines the inflammatory role of IL-4-primed macrophages［J］. Cell Rep， 2023， 42（5）： 112471. doi：10.1016/j.celrep.2023.112471 . doi: 10.1016/j.celrep.2023.112471
[25]	NIE X， SHEN C， TAN J， et al. Periostin： A potential therapeutic target for pulmonary hypertension？［J］. Circ Res， 2020， 127（9）： 1138-1152. doi：10.1161/CIRCRESAHA.120.316943 . doi: 10.1161/CIRCRESAHA.120.316943

目标细胞	圈门逻辑
嗜酸性粒细胞（EOS）	CD45⁺CD11b⁺SiglecF⁺
中性粒细胞（Neu）	CD45⁺CD11b⁺Ly6G⁺
巨噬细胞	CD45⁺CD11c⁺F4/80⁺
自然杀伤（NK）细胞	CD45⁺NK1.1⁺
B细胞	CD45⁺CD19⁺
细胞毒性T细胞（Tc）	CD45⁺CD3⁺CD8⁺
辅助性T细胞（Th）1	CD45⁺LIN⁺CD4⁺T^-bet⁺
Th2	CD45⁺LIN⁺CD4⁺GATA^-3⁺
Th17	CD45⁺LIN⁺CD4⁺RORγt⁺
固有淋巴细胞（ILC）1	CD45⁺LIN^-CD127⁺T^-bet⁺
ILC2	CD45⁺LIN^-CD127⁺GATA^-3⁺
ILC3	CD45⁺LIN^-CD127⁺RORγt⁺

抗体	公司
Fixable Viability Dye eFluor? 506	Invitrogen
CD45 Percp	Biolegend
CD11b FITC	Invitrogen
Siglec-F BV421	Invitrogen
Ly6G Alexa Fluor? 700	Invitrogen
F4/80 BV711	BD Biosciences
NK1.1 APC	Invitrogen
CD19 BV605	BD Biosciences
CD8 PE	Invitrogen
CD4 BV605	Invitrogen
Lineage FITC	Invitrogen
CD127 APC	Biolegend
T-bet PE	BD Biosciences
GATA-3 PE-Cy7	BD Biosciences
RORγt BV786	BD Biosciences

细胞群	对照组（n = 4）	h1w（n = 5）	h2w（n = 5）	h3w（n = 5）	h4w（n = 5）	F值	P值
CD3⁺T	25.83 ± 3.34	26.64 ± 1.39	25.18 ± 1.53	26.88 ± 0.56	18.94 ± 6.08^#	5.091	< 0.001
CD19⁺B	29.98 ± 7.07	29.08 ± 4.64	26.62 ± 2.18	26.80 ± 2.47	16.72 ± 7.14^*#	5.342	< 0.001
Neu	9.33 ± 2.02	13.42 ± 1.72^*#	18.00 ± 3.35^*#	13.90 ± 0.86^*#	33.48 ± 16.05^*#	7.270	< 0.001
CD8⁺T	4.90 ± 0.59	5.28 ± 0.72	5.07 ± 0.82	4.51 ± 0.63	4.63 ± 1.85	0.449	0.771
CD4⁺T	12.40 ± 1.63	14.26 ± 1.26	11.86 ± 0.56^*	13.12 ± 0.56^*	11.28 ± 2.03	3.827	0.019

细胞群	对照组（n = 4）	h1w（n = 5）	h2w（n = 5）	h3w（n = 5）	h4w（n = 5）	F值	P值
总巨噬细胞	2.51 ± 0.09	1.41 ± 0.22^*#	1.18 ± 0.15^*	1.03 ± 0.17^*	0.86 ± 0.39^*	32.84	< 0.001
AM	8.74 ± 2.59	17.40 ± 4.62^*#	26.28 ± 7.64^*	29.02 ± 4.32^*	32.82 ± 5.27^*	15.21	< 0.001
IM	91.03 ± 2.62	82.34 ± 4.63^*#	73.36 ± 7.12^*	70.48 ± 4.44^*	66.86 ± 5.22^*	15.23	< 0.001
EOS	1.87 ± 0.22	2.63 ± 0.39^*#	2.44 ± 0.35^*	2.37 ± 0.36^*	1.06 ± 0.31^*#	17.19	< 0.001
NK	9.30 ± 2.03	7.41 ± 0.75	7.98 ± 0.59	9.05 ± 1.77	7.98 ± 2.66	0.990	0.436
ILC	6.71 ± 0.47	5.50 ± 1.34	6.63 ± 0.72	6.67 ± 0.82	8.24 ± 1.61	3.890	0.017

Dynamic changes of immune cell subsets in a mouse model of Sugen-hypoxia-induced pulmonary hypertension

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 8

References 25

Related Articles 12

Recommended Articles

Metrics

Comments

[1]	Yang LIU,Changbo CHENG,Hongduo LU,Benlu CHEN,Zhiwen CHEN,Zhenqiu CHEN,Yinuo FAN. Research progress on immune cells and related cytokines mediated imbalance of bone homeostasis and its roles in bone-related diseases [J]. The Journal of Practical Medicine, 2026, 42(2): 276-284.
[2]	Qingyuan XU,Weifeng YUAN,Mu CHEN,Xiaoneng. MO. Research on the diagnostic value of pulmonary artery diameter characteristics and combined TNF-α in patients with HIV associated pulmonary hypertension [J]. The Journal of Practical Medicine, 2024, 40(13): 1869-1874.
[3]	DAI Shuang, FENG Yanhong.. Fully automated 3D ultrasound right ventricular quantitative software to evaluate right ventricular systolic function in patients with systemic lupus erythematosus [J]. The Journal of Practical Medicine, 2023, 39(5): 636-641.
[4]	LUO Zhi⁃ mei, LIU Hongyan, SUN Desheng.. Application of a pulmonary vascular gene knockdown animal model in pulmonary hypertension [J]. The Journal of Practical Medicine, 2023, 39(4): 404-409.
[5]	Huiqiang WEI,Liping GUO,Yankun HOU,Xiuling HAO,Haining LI,Yongna. CHAI. Risk factors of lung injury and pulmonary hypertension in patients with chronic obstructive pulmonary disease and the predictive value of serum SDF⁃1 and sRAGE [J]. The Journal of Practical Medicine, 2023, 39(24): 3214-3221.
[6]	LIU Zhenning, XU Yunyi, HU Lihuan, LIU Zhihui, HU Jinxing, LI Hua, GUAN Ping.. The clinical value of peripheral blood cell analysis and tuberculosis antibody detection in the diagnosis of pulmonary tuberculosis [J]. The Journal of Practical Medicine, 2023, 39(2): 262-266.
[7]	Xiaojun WU,Shimiao BU,Xiangting CHEN,Jun YU,Yong LIU,Yuehong ZHANG,Songqing XIN,Yufeng. LIU. Immune mapping changes in the development of diabetic retinopathy [J]. The Journal of Practical Medicine, 2023, 39(19): 2517-2523.
[8]	Ailifeire MAIMAITI,Jing GAO,Zixiang YU,Yitong. MA. Up⁃regulated miR⁃106b⁃5p in exosomes derived from pulmonary artery smooth muscle cells enhances Warburg effect of pulmonary artery endothelial cells and promotes arterial pulmonary hypertension [J]. The Journal of Practical Medicine, 2023, 39(17): 2190-2195.
[9]	DU Peng, ZHANG Xiangli, ZHU Yongfeng.. Predictive value of serum troponin I，and endothelin ⁃ 1 combined with hypoxia inducible factor ⁃ 1 α for heart failure [J]. The Journal of Practical Medicine, 2022, 38(24): 3077-3080.
[10]	XU Mingyan, HAN Xiaopeng, LIU Yingli, GAO Fan, LIU Jianbo.. Risk factors of pulmonary hypertension in acute exacerbation of chronic obstructive pulmonary disease [J]. The Journal of Practical Medicine, 2022, 38(19): 2467-2471.
[11]	HE Bo, TAN Ailin, HU Wenjuan, CHEN Xiaoguang, HUANG Xiaomin, CHEN Hanmei, HUANG Xiaoqin.. Expression of tissue factors on platelet surface during preparation and storage of platelet concentrates [J]. The Journal of Practical Medicine, 2021, 37(8): 1055-1059.
[12]	CHEN Chen, ZHANG Yanbei.. Alleviation of pulmonary vasculature injury induced by hypoxia⁃induced pulmonary hypertension via Rho kinase inhibitor combined with puerarin by inhibiting TGF⁃β1/Smads signaling pathway and inflammato⁃ ry response [J]. The Journal of Practical Medicine, 2021, 37(5): 591-595.